PT  - JOURNAL ARTICLE
AU  - Lee, Andrew
AU  - Mavaddat, Nasim
AU  - Cunningham, Alex P.
AU  - Carver, Tim
AU  - Archer, Stephanie
AU  - Walter, Fiona M.
AU  - Tischkowitz, Marc
AU  - Roberts, Jonathan
AU  - Usher-Smith, Juliet
AU  - Simard, Jacques
AU  - Schmidt, Marjanka K.
AU  - Devilee, Peter
AU  - Zadnik, Vesna
AU  - Jürgens, Hannes
AU  - Mouret-Fourme, Emmanuelle
AU  - De Pauw, Antoine
AU  - Rookus, Matti
AU  - Mooij, Thea M.
AU  - Pharoah, Paul P.D.
AU  - Easton, Douglas F.
AU  - Antoniou, Antonis C.
TI  - Enhancing the BOADICEA cancer risk prediction model to incorporate new data on <em>RAD51C, RAD51D, BARD1</em>, updates to tumour pathology and cancer incidences
AID  - 10.1101/2022.01.27.22269825
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.27.22269825
4099  - http://medrxiv.org/content/early/2022/01/28/2022.01.27.22269825.short
4100  - http://medrxiv.org/content/early/2022/01/28/2022.01.27.22269825.full
AB  - Background BOADICEA for breast cancer and the epithelial ovarian cancer (EOC) models included in the CanRisk tool (www.canrisk.org) provide future cancer risks based on rare pathogenic variants in cancer-susceptibility genes, polygenic risk scores, breast-density, questionnaire-based risk factors and family history. Here, we extend the models to include the effects of pathogenic variants in recently established breast cancer and EOC susceptibility genes, up-to-date age-specific pathology distributions and continuous risk factors.Methods BOADICEA was extended to further incorporate the associations of pathogenic variants in BARD1, RAD51C and RAD51D with breast cancer risk. The EOC model was extended to include the association of PALB2 pathogenic variants with EOC risk. Age-specific distributions of oestrogen-receptor-negative and triple-negative breast cancer status for pathogenic variant carriers in these genes and CHEK2 and ATM were also incorporated. A novel method to include continuous risk factors was developed, exemplified by including adult-height as continuous.Results BARD1, RAD51C and RAD51D explain 0.31% of the breast cancer polygenic variance. When incorporated into the multifactorial model, 34-44% of these carriers would be reclassified to the near-population and 15-22% to the high-risk categories based on the UK NICE guidelines. Including height as continuous, increased the BC relative-risk variance from 0.002 to 0.010.Conclusions These extensions will allow for better personalised risks for BARD1, RAD51C, RAD51D and PALB2 pathogenic variant carriers and more informed choices on screening, prevention, risk factor modification or other risk-reducing options.Competing Interest StatementThe authors ACA, DFE, AL, APC and TC are named inventors of BOADICEA v5 commercialised by Cambridge Enterprise.Funding StatementThis work has been supported by grants from Cancer Research UK (C12292/A20861 and PPRPGM-Nov20\100002); the European Union's Horizon 2020 research and innovation programme under grant agreement numbers 633784 (B-CAST) and 634935 (BRIDGES); the PERSPECTIVE I&I project, which the Government of Canada funds through Genome Canada (13529) and the Canadian Institutes of Health Research (155865), the Ministere de l'Economie et de l'Innovation du Quebec through Genome Quebec, the Quebec Breast Cancer Foundation, the CHU de Quebec Foundation and the Ontario Research Fund. The University of Cambridge receives salary support for PDPP from the NHS through the Clinical Academic Reserve. This research is linked to the CanTest Collaborative, which is funded by Cancer Research UK [C8640/A23385], of which FMW is Director.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo individual level data used. The algorithm development was performed using publicly available parameter estimates. The algorithms developed are freely available for use via www.canrisk.org